Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/207749
Title: | Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry'). |
Author: | Erton, Zeynep Belce Sevim, Ecem de Jesús, Guilherme Ramires Cervera i Segura, Ricard, 1960- Ji, Lan Lan Pengo, Vittorio Ugarte, Amaia Andrade, Danieli Andreoli, Laura Atsumi, Tatsuya Fortin, Paul R. Gerosa, Maria Zuo, Yu Petri, Michelle A. Sciascia, Savino Tektonidou, Maria Aguirre Zamorano, Mª. Ángeles Branch, D Ware Erkan, Doruk |
Keywords: | Embaràs Mort del fetus Avortament Lupus eritematós Síndrome antifosfolipídica Assaigs clínics Pregnancy Fetal death Abortion Lupus erythematosus Antiphospholipid syndrome Clinical trials |
Issue Date: | 14-Jun-2022 |
Publisher: | BMJ Publishing Group |
Abstract: | Objectives: To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since the inception of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Registry. Methods: We identified persistently aPL-positive patients recorded as 'pregnant' during prospective follow-up, and defined 'aPL-related outcome' as a composite of: (1) Preterm live delivery (PTLD) at or before 37th week due to pre-eclampsia (PEC), eclampsia, small-for-gestational age (SGA) and/or placental insufficiency (PI); or (2) Otherwise unexplained fetal death after the 10th week of gestation. The primary objective was to describe the characteristics of patients with and without aPL-related composite outcomes based on their first observed pregnancies following registry recruitment. Results: Of the 55 first pregnancies observed after registry recruitment among nulliparous and multiparous participants, 15 (27%) resulted in early pregnancy loss <10 weeks gestation. Of the remaining 40 pregnancies: (1) 26 (65%) resulted in term live delivery (TLD), 4 (10%) in PTLD between 34.0 weeks and 36.6 weeks, 5 (12.5%) in PTLD before 34th week, and 5 (12.5%) in fetal death (two associated with genetic anomalies); and (2) The aPL-related composite outcome occurred in 9 (23%). One of 26 (4%) pregnancies with TLD, 3/4 (75%) with PTLD between 34.0 weeks and 36.6 weeks, and 3/5 (60%) with PTLD before 34th week were complicated with PEC, SGA and/or PI. Fifty of 55 (91%) pregnancies were in lupus anticoagulant positive subjects, as well as all pregnancies with aPL-related composite outcome. Conclusion: In our multicentre, international, aPL-positive cohort, of 55 first pregnancies observed prospectively, 15 (27%) were complicated by early pregnancy loss. Of the remaining 40 pregnancies, composite pregnancy morbidity was observed in 9 (23%) pregnancies. |
Note: | Reproducció del document publicat a: https://doi.org/10.1136/lupus-2021-000633 |
It is part of: | Lupus Science & Medicine, 2022, vol. 9, num.1, e000633 |
URI: | https://hdl.handle.net/2445/207749 |
Related resource: | https://doi.org/10.1136/lupus-2021-000633 |
ISSN: | 2053-8790 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
258010.pdf | 683.82 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License